Comparing the Efficacy of Advanced Interleukin Inhibitors for Crohn’s Disease: A Systematic Review and Network Meta-Analysis
Journal of Clinical Medicine · 16.07.2026 · 15 (14) · 5593
DOI: 10.3390/jcm15145593 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 16.07.2026. Verfasst von Qiuyue Zhang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, West China Hospital of Sichuan University, Chengdu 610041, China. Die Arbeit nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: West China Hospital of Sichuan University, West China Hospital, Sichuan University.
Abstract (Originalsprache)
Background
IL-23p19 inhibitors have recently gained approval for treating moderate-to-severe Crohn’s disease (CD). Nevertheless, their comparative efficacy relative to each other and to the IL-12/23 inhibitor ustekinumab (UST) is controversial. Therefore, this study evaluated risankizumab (RZB), mirikizumab (MRK), guselkumab (GUS), and UST for inducing and maintaining clinical and endoscopic remission in the moderate-to-severe CD population.
Methods
PubMed, Embase, Web of Science, and Cochrane Library were searched until 4 November 2025. Risk ratios (RRs) with 95% confidence intervals (CIs) were calculated for dichotomous outcomes. The clinical and endoscopic remission/response during induction and maintenance phases was examined through a frequentist network meta-analysis (NMA). Subgroup analyses were carried out in the biologic-naïve population and those with prior biologic failure.
Results
This NMA included 15 RCTs within 11 studies with 7747 patients. Relative to UST, IL-23p19 inhibitors demonstrated superior efficacy during induction and maintenance therapy. For clinical remission during the induction, GUS < 600 mg displayed significantly greater efficacy than UST 6 mg/kg (RR: 1.34 [95% CI: 1.06–1.70]). For endoscopic remission during the induction, both RZB > 600 mg (RR: 1.66 [95% CI: 1.14–2.41]) and RZB ≤ 600 mg (RR: 1.65 [95% CI: 1.21–2.25]) were superior to UST 6 mg/kg. During maintenance therapy, 200 mg GUS achieved a higher rate of endoscopic remission than UST (RR: 2.04 [95% CI: 1.09–3.49]). According to the SUCRA rankings, IL-23p19 inhibitors, particularly GUS and RZB, consistently ranked above UST across all evaluated outcomes.
Conclusions
IL-23p19 inhibitors demonstrated superior efficacy in comparison to the IL-12/23 inhibitor UST in the moderate-to-severe CD population. Further high-quality, long-term, multicenter RCTs and real-world studies could confirm these findings.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastroenterology and Hepatology, West China Hospital of Sichuan University, Chengdu 610041, China.
ORCID-Profile: Qiuyue Zhang
Förderung
- West China Hospital of Sichuan University
- West China Hospital, Sichuan University
Zitieren
APA
Zhang, Q., Luo, M., & Wang, Y. (2026). Comparing the Efficacy of Advanced Interleukin Inhibitors for Crohn’s Disease: A Systematic Review and Network Meta-Analysis. Journal of Clinical Medicine, 15(14), 5593. https://doi.org/10.3390/jcm15145593
Vancouver
Zhang Q, Luo M, Wang Y. Comparing the Efficacy of Advanced Interleukin Inhibitors for Crohn’s Disease: A Systematic Review and Network Meta-Analysis. Journal of Clinical Medicine. 2026;15(14):5593. doi:10.3390/jcm15145593
BibTeX
@article{Zhang2026,
author = {Zhang, Qiuyue and Luo, Mengqi and Wang, Yufang},
title = {Comparing the Efficacy of Advanced Interleukin Inhibitors for Crohn’s Disease: A Systematic Review and Network Meta-Analysis},
journal = {Journal of Clinical Medicine},
year = {2026},
volume = {15},
number = {14},
pages = {5593},
doi = {10.3390/jcm15145593}
}
EUVIMED